Investigational drug · Phase 2
UC-MSC
Also called: RY_SW01 cell, Human umbilical cord mesenchymal stem cells, umbilical cord mesenchymal stem cell
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
94
Any phase or sponsor naming "UC-MSC"
First trial start
2023
Jul 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "UC-MSC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome
- Lupus Nephritis
- Spinocerebellar Ataxia Type 1
- Spinocerebellar Ataxia Type 2
- Spinocerebellar Ataxia Type 3
- Spinocerebellar Ataxia Type 6
- Decompensated Liver Cirrhosis
- Decompensated Hepatitis B Cirrhosis
- Arteriovenous Fistula Stenosis
- Systemic Sclerosis
Approved drugs for the same conditions: Lupus (SLE) · Hepatitis B · Neurology · Immunology and inflammation · Infectious disease and vaccines · Rare and genetic disease · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "UC-MSC" as an intervention, largest first.
Alliancells Bioscience Corporation LimitedIndustry
NCT01573923 · 320 participants (planned) · Start Jul 2014 · Primary completion Jul 2015
Drug: mesenchymal stem cells; Conventional therapy · For: Liver Cirrhosis
Sites: Beijing, China; Lanzhou, China; Qionghai, China · 6 sites in all
- Umbilical Cord Mesenchymal Stem Cells for Patients With Liver CirrhosisPivotal-lookingCompleted
Beijing 302 HospitalAcademic, hospital or other
NCT01220492 · 266 participants · Start May 2009 · Primary completion Apr 2016
Drug: conventional plus MSC treatment; conventional plus placebo treatment · For: Liver Cirrhosis
Sites: Beijing, China
- UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver FailurePivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT02812121 · 261 participants (planned) · Start Jun 2016 · Primary completion Jun 2017
Drug: umbilical cord blood mesenchymal stem cells · For: Liver Failure
- Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver CirrhosisStatus unknown
Shandong Qilu Stem Cells Engineering Co., Ltd.Industry
NCT03529136 · 252 participants (planned) · Start Jun 1, 2018 · Primary completion Dec 31, 2019
Drug: UC-MSC · For: Decompensated Liver Cirrhosis
- Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver FailurePivotal-lookingStatus unknown
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT01844063 · 210 participants (planned) · Start Jul 2013 · Primary completion Jan 2016
Drug: Conventional treatment · For: Liver Failure
Sites: Guangzhou, China
- Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid ArthritisStatus unknown
Alliancells Bioscience Corporation LimitedIndustry
NCT01547091 · 200 participants (planned) · Start Apr 2013 · Primary completion Oct 2014
Drug: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs); Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) and 1 more · For: Rheumatoid Arthritis
Sites: Xi'an, China
- Mesenchymal Stem Cells Treatment for Decompensated Liver CirrhosisPivotal-lookingStatus unknown
Beijing 302 HospitalAcademic, hospital or other
NCT03945487 · 200 participants (planned) · Start May 20, 2019 · Primary completion Dec 30, 2021
Drug: umbilical cord-derived mesenchymal stem cell · For: Decompensated Liver Cirrhosis
Sites: Beijing, China
- Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm InfantsPivotal-lookingNot yet recruiting
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT07058025 · 168 participants (planned) · Start Oct 1, 2025 · Primary completion Sep 30, 2028
Drug: Human Allogenic Umbilical Cord Mesenchymal Stromal Cells · For: Bronchopulmonary Dysplasia (BPD); ELGAN (22-28SA)
Sites: Edmonton, Canada; Hamilton, Canada; Ottawa, Canada · 8 sites in all
- Mesenchymal Stem/Stromal Cell Therapy in the Treatment of FrailtyPivotal-lookingCompleted
Vinmec Research Institute of Stem Cell and Gene TechnologyAcademic, hospital or other
NCT04919135 · 158 participants · Start Oct 19, 2021 · Primary completion Apr 20, 2023
Drug: Umbilical Cord Mesenchymal Stem Cells transplantation; standard frailty treatment and supplementary medication · For: Frailty
Sites: Hanoi, Vietnam
- Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual DeficiencyPivotal-lookingStatus unknown
Vinmec Research Institute of Stem Cell and Gene TechnologyAcademic, hospital or other
NCT05345418 · 158 participants (planned) · Start Apr 1, 2022 · Primary completion Jun 1, 2025
Drug: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency · For: Sexual Dysfunction Male
Sites: Hanoi, Vietnam
Newest research
PubMed records naming it or its code names, newest first.
- Ultrasound-responsive nanotherapy promotes axonal regeneration after SCI via reactivating CREB/miR-129-5p signaling.
Gu G, Zhu H, Li S, et al. · Bioact Mater 2027
- Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles delivering CERS1 promote squamous differentiation in HPV16-positive cervical intraepithelial neoplasia via remodeling sphingomyelin metabolism.
Yang H, Chen W, Liu L, et al. · Mater Today Bio 2026
- Therapeutic potential of umbilical cord-derived MSCs in arthritis: Insights from preclinical and clinical studies.
Greene DL, Habiba UE, Sathyanarayanan R, et al. · Regen Ther 2026
- Synovial Biomarker Modulation and Clinical Response to Umbilical Cord-Derived MSC Treatment in Knee Osteoarthritis: A Case Series Study.
vajger U, Kolar M, Pompe B, et al. · Cartilage 2026
- Exosomes derived from AHR-overexpressing human umbilical cord mesenchymal stem cells attenuate H/R injury via AHR/NLRP3 pathway.
Qin Y, Shen D, Guo K, et al. · Cell Cycle 2026
- Stem cell-derived EVs in the treatment of pulmonary fibrosis: from mechanistic insights to clinical-grade manufacturing and nebulized delivery.
Zhu Y, Pan Y, Wang X, et al. · Expert Rev Respir Med 2026
Also in development for Acute Respiratory Distress Syndrome
- STSA-1002Phase 32 trials
Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome
- AtibuclimabIC14Phase 24 trials
Implicit Bioscience · Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- rhu-pGSNrecombinant human gelsolin, Recombinant human plasma gelsolin pre-exposurePhase 22 trials
BioAegis Therapeutics Inc. · Acute Respiratory Distress Syndrome, Infections, Decompression Sickness
- vilobelimabPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- AV-001Phase 21 trial
Vasomune Therapeutics, Inc. · Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.